2-benzyl-3-ethoxy-2-hydroxy-3-oxopropanoic acid | 252730-57-7

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: 2-benzyl-3-ethoxy-2-hydroxy-3-oxopropanoic acid
• CAS: 252730-57-7
• 化学式: C₁₂H₁₄O₅
• 分子量: 238.24
• InChiKey: HOSNVJQPMAOZEN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  83.8
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-benzyl-3-ethoxy-2-hydroxy-3-oxopropanoic acid 170.0 ℃ 、2.0 kPa 条件下， 反应 3.0h， 生成 2-羟基-3-苯基丙酸乙酯
  参考文献：
  名称：

  Mild air-oxidation of 1,3-dicarbonyl compounds with cesium salts: Novel α-hydroxylation accompanied by partial hydrolysis of malonate derivatives

  摘要：

  13-Dicarbonyl compounds (1) were: efficiently oxygenated at the alpha-position with cesium salts, such as CsF or Cs2CO3 (0.1 Meq) in DMF at room temperature. Reaction of malonate derivatives (1a, b) with excess amount (2 Meg) of Cs2CO3 gave alpha-hydroxylmonoester (3) formed by oxygenation and partial hydrolysis, which was decarboxylated to a lactic acid derivative (5). (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(99)01618-4
• 作为产物：
  描述：

  苄基丙二酸二乙酯 在 cesium fluoride 、 potassium hydroxide 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 72.0h， 生成 2-benzyl-3-ethoxy-2-hydroxy-3-oxopropanoic acid
  参考文献：
  名称：

  发现新的恶唑烷二酮衍生物作为有效的和选择性的盐皮质激素受体拮抗剂

  摘要：

  新颖恶唑烷二酮类似物被发现为有效的和选择性盐皮质激素受体（MR）拮抗剂。结构-活性关系（SAR）研究的重点是提高效力和微粒体的稳定性。选定的化合物表现出出色的MR活性，合理的核激素受体选择性和可接受的大鼠药代动力学。

  DOI：

  10.1016/j.bmcl.2013.05.077

文献信息

• [EN] MINERALOCORTICOID RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES D'UN RÉCEPTEUR DES MINÉRALOCORTICOÏDES
  申请人：MERCK SHARP & DOHME

  公开号：WO2013055607A1

  公开（公告）日：2013-04-18

  The present invention is directed to compounds of the Formula (I) as well as pharmaceutically acceptable salts thereof, that are aldosterone receptor antagonists which might be useful for treating aldosterone-mediated diseases. The invention furthermore relates to processes for preparing compounds of the Formula (I), to their possible use for the treatment of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of the Formula (I).

  本发明涉及式(I)的化合物以及其药用盐，这些化合物是醛固酮受体拮抗剂，可能对治疗醛固酮介导的疾病有用。该发明还涉及制备式(I)化合物的方法，以及它们可能用于治疗上述疾病和制备用于此目的的药物的方法，以及包括式(I)化合物的药物组合物。
• [EN] MINERALOCORTICOID RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DE RÉCEPTEUR DES MINÉRALOCORTICOÏDES
  申请人：MERCK SHARP & DOHME

  公开号：WO2013055606A1

  公开（公告）日：2013-04-18

  The present invention is directed to compounds of the Formula (I) as well as pharmaceutically acceptable salts thereof, that are potentially useful for treating aldosterone-mediated diseases. The invention furthermore relates to processes for preparing compounds of the Formula (I), to their possible use in the treatment of the above mentioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of the Formula (I).

  本发明涉及式（I）的化合物及其药学上可接受的盐，这些化合物可能有用于治疗醛固酮介导的疾病。本发明还涉及制备式（I）的化合物的过程，以及它们在治疗上述疾病和制备药物目的中的可能用途，以及包括式（I）的化合物的药物组合物。
• Discovery of novel oxazolidinedione derivatives as potent and selective mineralocorticoid receptor antagonists
  作者：Christine Yang、Hong C. Shen、Zhicai Wu、Hong D. Chu、Jason M. Cox、Jaume Balsells、Alejandro Crespo、Patricia Brown、Beata Zamlynny、Judyann Wiltsie、Joseph Clemas、Jack Gibson、Lisa Contino、JeanMarie Lisnock、Gaochao Zhou、Margarita Garcia-Calvo、Tom Bateman、Ling Xu、Xinchun Tong、Martin Crook、Peter Sinclair

  DOI：10.1016/j.bmcl.2013.05.077

  日期：2013.8

  Novel oxazolidinedione analogs were discovered as potent and selective mineralocorticoid receptor (MR) antagonists. Structure–activity relationship (SAR) studies were focused on improving the potency and microsomal stability. Selected compounds demonstrated excellent MR activity, reasonable nuclear hormone receptor selectivity, and acceptable rat pharmacokinetics.

  新颖恶唑烷二酮类似物被发现为有效的和选择性盐皮质激素受体（MR）拮抗剂。结构-活性关系（SAR）研究的重点是提高效力和微粒体的稳定性。选定的化合物表现出出色的MR活性，合理的核激素受体选择性和可接受的大鼠药代动力学。
• Mineralocorticoid receptor antagonists
  申请人：Merck Sharp & Dohme Corp.

  公开号：US09085568B2

  公开（公告）日：2015-07-21

  The present invention is directed to compounds of the Formula (I) as well as pharmaceutically acceptable salts thereof that are possible useful for treating aldosterone-mediated diseases. The invention furthermore relates to processes for preparing compounds of the Formula (I), to their possible use for the treatment of the above mentioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of the Formula (I).

  本发明涉及公式（I）的化合物及其药学上可接受的盐，这些化合物可能有用于治疗醛固酮介导的疾病。此外，本发明还涉及制备公式（I）化合物的过程，以及它们可能用于治疗上述疾病和制备用于此目的的药物，并且涉及包含公式（I）化合物的制药组合物。
• MINERALOCORTICOID RECEPTOR ANTAGONISTS
  申请人：MERCK SHARP & DOHME CORP.

  公开号：US20150166490A1

  公开（公告）日：2015-06-18

  The present invention is directed to compounds of the Formula I as well as pharmaceutically acceptable salts thereof, that are potentially useful for treating aldosterone-mediated diseases. The invention furthermore relates to processes for preparing compounds of the Formula I, to their possible use in the treatment of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of the Formula I.

  本发明涉及式I化合物及其药学上可接受的盐，这些化合物可能有助于治疗醛固酮介导的疾病。此外，本发明还涉及制备式I化合物的方法，其可能用于治疗上述疾病和制备药物，以及包含式I化合物的药物组合物。